Sign In
Buy RCKT
$3.11
-0.100 (-3.12%)
At Close: Jul 31, 2026
RCKT's Q4 Loss Narrower Than Estimated, Pipeline in Focus
01:50pm, Friday, 27'th Feb 2026
Rocket Pharmaceuticals reports narrower-than-estimated Q4 loss. The company provides key updates on its pipeline candidates.
Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Receives Average Rating of “Hold” from Analysts
01:58am, Friday, 27'th Feb 2026
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT - Get Free Report) has been given an average recommendation of "Hold" by the seventeen research firms that are presently covering the firm, MarketBeat Rating
Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Progress
04:00pm, Thursday, 26'th Feb 2026
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disord
Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences
07:00am, Monday, 23'rd Feb 2026
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disord
Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Receives Average Recommendation of “Hold” from Brokerages
02:00am, Monday, 02'nd Feb 2026
Shares of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT - Get Free Report) have received a consensus rating of "Hold" from the seventeen analysts that are presently covering the stock, MarketBeat Ratings
Rocket Pharmaceuticals (NASDAQ:RCKT) Stock Price Crosses Above Fifty Day Moving Average – Here’s Why
03:32am, Saturday, 24'th Jan 2026
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT - Get Free Report)'s stock price passed above its 50 day moving average during trading on Friday. The stock has a 50 day moving average of $3.43 and traded a
Rocket Pharmaceuticals, Inc. (RCKT) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
05:16pm, Wednesday, 14'th Jan 2026
Rocket Pharmaceuticals, Inc. (RCKT) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
3 cheap stocks that could turn $1,000 into $10,000
09:23am, Wednesday, 14'th Jan 2026
At the start of 2025, the stock market appeared unstable as most major assets were, seemingly, very overvalued. Despite this, there was no shortage of opportunities for savvy investors to find underva
Rocket Pharmaceuticals to Participate in the 44th Annual J.P. Morgan Healthcare Conference
07:00am, Monday, 05'th Jan 2026
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disord
Rocket Pharmaceuticals: Deep Dislocation Offers Asymmetric Upside On LAD-I Approval And Amended Danon Program
10:23am, Friday, 26'th Dec 2025
Rocket Pharmaceuticals is rated Buy with a $17 price target, reflecting a deep disconnect between intrinsic value and current valuation. RCKT's bullish thesis hinges on a high-probability LAD-1 approv
Rocket Pharmaceuticals to Participate in the 8th Annual Evercore Healthcare Conference
07:00am, Tuesday, 25'th Nov 2025
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disord
Rocket Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights Recent Progress
04:00pm, Thursday, 06'th Nov 2025
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disord
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Rocket (RCKT) To Contact Him Directly To Discuss Their Options If you are a long-term st
RCKT Stock Up as FDA Accepts Resubmitted BLA for Gene Therapy
12:35pm, Wednesday, 15'th Oct 2025
Rocket Pharmaceuticals surges as the FDA accepts its resubmitted BLA for Kresladi, a gene therapy targeting the rare LAD-I disorder.
FDA Acceptance Of Rocket Pharmaceuticals' Lead Gene Therapy Application Reestablishes Momentum For Stock
02:27pm, Tuesday, 14'th Oct 2025
On Tuesday, the U.S. Food and Drug Administration (FDA) accepted Rocket Pharmaceuticals, Inc.'s (NASDAQ:RCKT) resubmission of the Biologics License Application (BLA) for Kresladi (marnetegragene autot
